Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebe

Showing results (361-370 of 372) with videos related to

Pageof 38
Sort By:
Nature Communications|January 9, 2016
Reprogramming triggers endogenous L1 and Alu retrotransposition in human induced pluripotent stem cellsSabine Klawitter, Nina V Fuchs, Kyle R Upton, et al.
Nature Communications|December 21, 2018
Author Correction: Reprogramming triggers endogenous L1 and Alu retrotransposition in human induced pluripotent stem cellsSabine Klawitter, Nina V Fuchs, Kyle R Upton, et al.
The Lancet. Infectious Diseases|July 11, 2025
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trialNorbert Heinrich, Christina Manyama, Simon E Koele, et al.
The Lancet. Infectious Diseases|July 11, 2025
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trialLilian Tina Minja, Isabella van der Feltz, Christina Manyama, et al.
World Journal of Urology|July 8, 2015
The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgeryPierre Bigot, Jean-Christophe Bernhard, Inderbir S Gill, et al.
Plos Medicine|March 19, 2024
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trialZoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 25, 2021
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TBC D Tweed, G H Wills, A M Crook, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 6, 2022
Pest population dynamics are related to a continental overwintering gradientDouglas Lawton, Anders S Huseth, George G Kennedy, et al.
Human Mutation|March 21, 2020
Damaging de novo missense variants in EEF1A2 lead to a developmental and degenerative epileptic-dyskinetic encephalopathyGemma L Carvill, Katherine L Helbig, Candace T Myers, et al.
The Journal of Infectious Diseases|June 27, 2022
Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition RiskZoe Moodie, One Dintwe, Sheetal Sawant, et al.
Pageof 38

Showing results (361-370 of 372) with videos related to

Sort By:
Pageof 38
Nature Communications|January 9, 2016
Reprogramming triggers endogenous L1 and Alu retrotransposition in human induced pluripotent stem cellsSabine Klawitter, Nina V Fuchs, Kyle R Upton, et al.
Nature Communications|December 21, 2018
Author Correction: Reprogramming triggers endogenous L1 and Alu retrotransposition in human induced pluripotent stem cellsSabine Klawitter, Nina V Fuchs, Kyle R Upton, et al.
The Lancet. Infectious Diseases|July 11, 2025
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trialNorbert Heinrich, Christina Manyama, Simon E Koele, et al.
The Lancet. Infectious Diseases|July 11, 2025
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trialLilian Tina Minja, Isabella van der Feltz, Christina Manyama, et al.
World Journal of Urology|July 8, 2015
The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgeryPierre Bigot, Jean-Christophe Bernhard, Inderbir S Gill, et al.
Plos Medicine|March 19, 2024
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trialZoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 25, 2021
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TBC D Tweed, G H Wills, A M Crook, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 6, 2022
Pest population dynamics are related to a continental overwintering gradientDouglas Lawton, Anders S Huseth, George G Kennedy, et al.
Human Mutation|March 21, 2020
Damaging de novo missense variants in EEF1A2 lead to a developmental and degenerative epileptic-dyskinetic encephalopathyGemma L Carvill, Katherine L Helbig, Candace T Myers, et al.
The Journal of Infectious Diseases|June 27, 2022
Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition RiskZoe Moodie, One Dintwe, Sheetal Sawant, et al.
Pageof 38